Promega, a manufacturer of enzymes and other products for biotechnology and molecular biology, with a portfolio covering the fields of genomics, protein analysis and much more, will launch A ...

The MSI-NGS panel showed 97% accuracy, with 112 patients exhibiting consistent MSI status between samples. In both surgical and biopsy samples, 3% of patients had MSI-high by MSI-NGS but ...

MADISON, Wis.--(BUSINESS WIRE)--A new microsatellite instability (MSI) system launched today by Promega Corporation enables cancer researchers to evaluate a new set of unique MSI markers that may ...

Oncologists and pathologists can use FDA-cleared microsatellite instability (MSI) diagnostic to screen for Lynch syndrome in patients with colorectal cancer MADISON, Wis.--(BUSINESS WIRE)--Promega ...

One in every three people is expected to have cancer in their lifetime, making it a major health concern for mankind. A crucial indicator of the outcome of cancer is its tumor microsatellite ...

Researchers from Johns Hopkins University have shown that a new panel of long mononucleotide repeats (LMR) might offer advantages over traditional microsatellite instability (MSI) detection methods in ...

Merck, known as MSD outside the United States and Canada, announced today that the European Commission has approved KEYTRUDA, Merck’ s anti-PD-1 therapy, as a monotherapy for the first-line treatment ...

First Positive Head-to-Head Phase 3 Trial Comparing a Single-Agent Cancer Medicine to Standard of Care Chemotherapy as First-line Treatment for MSI-H or dMMR Colorectal Cancer Merck to Share Data from ...

MSI has rapidly advanced as an important pan tumor biomarker associated with response to immune checkpoint inhibitors and the drive towards universal tumor testing. Join Session 3 to learn more about ...